IDWEEK 2016 - Adult Infectious Diseases

AKI Frequency in Critically Ill Assessed for 2 Antibiotic Regimens

By October 07, 2017

The authors gathered clinical and demographic data from the University of Kentucky Center for Clinical and Translational Science Enterprise Data Trust, for adults who received TZP+VAN or CFP+VAN for ≥48 hours in the ICU.

Emerging Viruses: 'Any Outbreak, Anywhere in the World, Can Be a Threat, Everywhere'

By October 30, 2016

With international travel, "any outbreak, anywhere in the world can be a threat, everywhere." That's the reality of an increasingly connected world, said Malik Peiris, PhD, of the School of Public Health at the HKU-Pasteur Research Center, The University of Hong Kong, Pokfulam, Hong Kong, at IDWeek 2016.

Low Risk of Hepatic Decompensation With PrOD Regimen, Study Finds

By October 30, 2016

The overall risk of hepatic decompensation in patients treated with the paritaprevir/ritonavir, ombitasvir, dasabuvir (PrOD) regimen during and up to 12 weeks after completion of treatment was low, Adeel A. Butt, MD, MS, of the VA Pittsburgh Healthcare System, Pittsburgh, PA, told IDWeek 2016 attendees.

IDWEEK 2016 - Pediatric Infectious Diseases

Is Extended-Interval Aminoglycoside Dosing Safe in Pediatric Patients?

By October 30, 2016

Extended-interval aminoglycoside dosing "appears of be safe in pediatric patients," a retrospective study presented at IDWeek has found.

Which Antibiotics Up Risk of AKI in Pediatric Oncology Patients?

By October 30, 2016

In children with cancer, concurrent vancomycin and piperacillin-tazobactam administration may increase risk of acute kidney injury, a retrospective study presented at IDWeek has shown.

Antivirals Underutilized in Children With Outpatient Influenza-Like Illness

By October 29, 2016

Children presenting with outpatient influenza-like illness rarely received an antiviral prescription, according to a retrospective cohort study presented at IDWeek 2016.


Combo Treatment Assessed in Black Patients Co-Infected With HIV, HCV

By October 08, 2017

Retrospective chart reviews were conducted for Black, genotype 1 (GT1), HIV/HCV co-infected patients treated with ledipasvir/sofosbuvir (LDV/SOF) at 3 hospitals.

Long-Term PPI Use Discouraged for HIV-1-Infected Patients

By October 30, 2016

Long-term use of proton pump inhibitors (PPIs) might increase microbial translocation and innate immune activation but not enterocyte turnover or T-cell activation among people infected with HIV-1, according to research findings reported at IDWeek 2016.

Antiviral Activity of Elbasvir/Grazoprevir Unaffected by HIV/HBV Drugs

By October 30, 2016

HIV and hepatitis B virus (HBV) drugs had no impact on antiviral activity of grazoprevir or elbasvir, and neither agent affected HIV and HBV replication, a study presented at IDWeek has shown.

IDWEEK 2016 - Vaccines

Promising Efficacy for Meningococcal Vaccine Candidate Among Adolescents

By October 30, 2016

GSK Vaccines' investigational meningococcal vaccine against serogroups A, B, C, W and Y (MenABCWY) is broadly effective among adolescents, according to the company's phase 2b, observer-blind, multicenter study, reported at IDWeek 2016.

Missed Chances for Hep A, B Vaccinations Could Harm HCV/HIV Co-Infected Patients

By October 30, 2016

Opportunities to vaccinate against Hepatitis A virus were missed in more than half of patients with HIV and Hepatitis C virus co-infection, researchers reported at IDWeek 2016.

Two MMR Vaccines Compared in Phase 3 Non-Inferiority Trial

By October 29, 2016

GSK's investigational combined measles, mumps, and rubella (MMR) vaccine (GSK_MMR) "demonstrated an acceptable immune response" that was non-inferior to Merck's MMR vaccine (MRK_MMR), a multinational, randomized, Phase 3A, controlled, observer-blinded study reported at IDWeek 2016 has shown.

IDWeek 2016 Videos